Rosiglitazone maleate

• CAT Number: A000404
• CAS Number: 155141-29-0
• Molecular Formula: C18H19N3O3S • C4H4O4
• Molecular Weight: 473.50
• Purity: ≥95%
• Synonyms: BRL 49653
• Target: PPAR
• Solubility: >23.7mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: (Z)-but-2-enedioic acid;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• InChI: InChI=1S/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1-
• InChIKey: SUFUKZSWUHZXAV-BTJKTKAUSA-N
• SMILES: CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3.C(=C\C(=O)O)\C(=O)O

Rosiglitazone maleate（Cat No.:A000404）is an oral medication primarily used to manage type 2 diabetes. It belongs to the thiazolidinedione class and functions as a selective agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in muscle and adipose tissues. By enhancing glucose uptake and reducing insulin resistance, rosiglitazone helps control blood sugar levels. However, its use has been associated with potential cardiovascular risks, leading to stricter prescribing guidelines. Ongoing research continues to explore its long-term effects and potential applications in metabolic disorders beyond diabetes management.